Currently, two mAbs against VEGF have been approved for the treatment of NSCLC, including bevacizumab against VEGF-A and ramucirumab against VEGFR-2 (Garcia et al., 2020) (Table 1). Here, VEGFA is linked to non-small cell lung carcinoma.